Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.
GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.
Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.
Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.
Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.
Rhea-AI Summary
GeoVax Labs, Inc. (GOVX) will report its 2023 financial results on February 29, 2024, after U.S. markets close. The company, a clinical-stage biotechnology firm, specializes in developing immunotherapies and vaccines for cancer and infectious diseases. A live conference call and webcast will follow the financial report for a corporate update and Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference in New York. The company will also conduct one-on-one meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces strengthening of intellectual property assets for its cancer immunotherapy program, Marburg virus, and HIV vaccines. The company received patent approvals from the Japanese Patent Office and the U.S. Patent and Trademark Office for various technologies related to immunotherapies and vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
GeoVax Labs, Inc. announces positive initial safety and immune response findings from its Phase 2 clinical trial for its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine, showed no serious adverse events and documented statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, including Delta and Omicron XBB 1.5. GEO-CM04S1 is designed to induce both antibody and T-cell responses to protect against severe disease caused by continually emerging variants of Covid-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced a 1-for-15 reverse stock split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The reverse split will be effective on January 30, 2024, with the Common Stock expected to begin trading on the split-adjusted basis on the Nasdaq Stock Exchange at the market open on January 31, 2024. The total number of issued and outstanding shares of Common Stock will be reduced proportionately from 29,757,823 shares to approximately 1,983,855 shares. The reverse split will not affect the rights and privileges of the holders of shares of Common Stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) strengthens its team by appointing Dr. J. Marc Pipas, M.D., as the Executive Medical Director, Oncology, to support the clinical development and regulatory approval of Gedeptin® and other immune-oncology programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer. The study demonstrated safety, tolerability, and stabilization or shrinkage of injected tumors in patients receiving multiple cycles of Gedeptin, leading to expanded development for monotherapy and combination therapy. GeoVax plans to proceed with further Gedeptin investigations, including adjustments to the treatment regimen and combination with immune checkpoint inhibitors in advanced head and neck cancer, as well as for additional cancerous and non-cancerous tumor indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GeoVax Labs, a biotechnology company (Nasdaq: GOVX), has been issued Patent No. 11,857,611 by the U.S. Patent and Trademark Office for a multiple component vaccine to prevent and treat malaria. The patent covers compositions and methods utilizing GeoVax's modified vaccinia Ankara (MVA) vector expressing Plasmodium antigens. The company aims to address the global public health threat of malaria, which causes 227 million infections and 619,000 deaths annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) to Present at Biotech Showcase and J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) expands its License Agreement with the National Institute of Allergy and Infectious Diseases to include Mpox and smallpox as additional indications for the development of a vaccine against SARS-CoV-2 (COVID-19). The amendment allows GeoVax to use materials and patent rights owned by the National Institutes of Health in combination with the Company’s proprietary technology for the creation of preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccines. The expansion offers the potential for a simplified vaccine regimen for protection against diseases associated with SARS-CoV-2 and orthopoxviruses, providing a significant opportunity for GeoVax's ongoing COVID-19 vaccine program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of GeoVax Labs Warrants (GOVXW)?
The current stock price of GeoVax Labs Warrants (GOVXW) is $0.1245 as of December 20, 2024.
What is GeoVax Labs, Inc. focused on developing?
GeoVax Labs, Inc. is focused on developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers using innovative proprietary platforms.
What recent achievements has GeoVax Labs, Inc. made?
GeoVax Labs, Inc. achieved positive initial safety and immune response findings in a Phase 2 clinical trial for its COVID-19 vaccine.
Which diseases are targeted by GeoVax's vaccine development programs?
GeoVax targets infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), Zika virus, along with developing immunotherapies for various solid tumors.
GeoVax Labs, Inc. Warrants